Can a simple vaccine boost immunity in CAR T-Cell patients?
NCT ID NCT04745559
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 23 times
Summary
This study looks at whether giving a pneumococcal vaccine (PCV13) before and after CAR T-cell therapy can improve the body's ability to fight off pneumococcus bacteria. It involves 26 adults with certain types of lymphoma who are scheduled for CAR T-cell treatment. The main goal is to see if the vaccine helps create a stronger immune response by day 90 after therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.